Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anatole Besarab

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Nephrology News & Issues|March 22, 2014
Non-intravenous approaches to iron therapy in chronic kidney disease: will it improve the benefit-to-risk ratio?Anatole Besarab
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2002
Iron sucrose: the oldest iron therapy becomes newJerry Yee, Anatole Besarab
Nephrology News & Issues|August 19, 2006
Changes noted to KDOQI guidelines for vascular accessAnatole Besarab, Lesley Dinwiddie
Kidney International|February 16, 2011
Candidate biomarkers for erythropoietin response in end-stage renal diseaseAnatole Besarab, Jerry Yee
Kidney International|October 1, 2014
Vascular access cannulation practices and outcomesAnatole Besarab, Lalathaksha Kumbar
Seminars in Dialysis|July 2, 2014
Uses and interpretation of iron studies in patients on chronic dialysisAnatole Besarab, Lynda Szczech
Clinical Journal of the American Society of Nephrology : CJASN|December 1, 2010
Catheter management in hemodialysis patients: delivering adequate flowAnatole Besarab, Rahul Pandey
Nature Clinical Practice. Nephrology|August 26, 2006
Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients?Anatole Besarab, Sandeep Soman
Seminars in Dialysis|October 5, 2016
What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal DiseaseAnatole Besarab, Lynda Szczech
Clinical Journal of the American Society of Nephrology : CJASN|April 20, 2013
Lifting the veil: insights into vascular access optionsLalathaksha Kumbar, Anatole Besarab
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Nephrology News & Issues|March 22, 2014
Non-intravenous approaches to iron therapy in chronic kidney disease: will it improve the benefit-to-risk ratio?Anatole Besarab
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2002
Iron sucrose: the oldest iron therapy becomes newJerry Yee, Anatole Besarab
Nephrology News & Issues|August 19, 2006
Changes noted to KDOQI guidelines for vascular accessAnatole Besarab, Lesley Dinwiddie
Kidney International|February 16, 2011
Candidate biomarkers for erythropoietin response in end-stage renal diseaseAnatole Besarab, Jerry Yee
Kidney International|October 1, 2014
Vascular access cannulation practices and outcomesAnatole Besarab, Lalathaksha Kumbar
Seminars in Dialysis|July 2, 2014
Uses and interpretation of iron studies in patients on chronic dialysisAnatole Besarab, Lynda Szczech
Clinical Journal of the American Society of Nephrology : CJASN|December 1, 2010
Catheter management in hemodialysis patients: delivering adequate flowAnatole Besarab, Rahul Pandey
Nature Clinical Practice. Nephrology|August 26, 2006
Does full versus partial correction of anemia have additional cardiac benefit in incident hemodialysis patients?Anatole Besarab, Sandeep Soman
Seminars in Dialysis|October 5, 2016
What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal DiseaseAnatole Besarab, Lynda Szczech
Clinical Journal of the American Society of Nephrology : CJASN|April 20, 2013
Lifting the veil: insights into vascular access optionsLalathaksha Kumbar, Anatole Besarab
Pageof 9